Pfizer CEO Bourla Wants Profit From COVID-19 Vaccine
Executive Summary
Several countries already are calling about orders, as the company prepares to begin a Phase III trial of its mRNA coronavirus vaccine candidate.
You may also be interested in...
Pfizer To Learn From Pandemic For Health Equity Initiative
The “Accord for a Healthier World” pledges to provide patent-protected medicines on a not-for-profit basis in 45 lower-income nations. Pfizer, which profited most from the COVID-19 pandemic, sees the pandemic experience as a way to advance health equity.
Pfizer’s US Contract Sets The Financial Bar For COVID-19 Vaccines
The US government’s order of 100 million doses for $1.95bn means the implied price for Pfizer/BioNtech's vaccine is $19.50 per dose. That could set a benchmark for solid near-term revenue and profitability for companies in the space.
Coronavirus Vaccine Efficacy Rate Set At 50% Because That’s What US FDA ‘Could Tolerate’
CBER Director Marks explains that too high a bar might result in natural herd immunity before vaccine trials could be completed, while too low a threshold could result in approval of products with limited efficacy.